Several drugs targeting lipid metabolism have been developed for the treatment of prostate cancer, including statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and sterol regulatory element-binding protein (SREBP) inhibitors (59–61). Here, CNBP is linked to prostate carcinoma.